Loading
Life sciences · Journal article
Theoretical and Natural Science · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Ionizable lipid nanoparticles (LNP)-mediated siRNA delivery provides a promising technological platform for cancer gene therapy. Traditional cancer treatment methods primarily focus on directly killing tumor cells, but RNA interference-based siRNA therapy can regulate the expression of genes related to disease, representing a therapeutic strategy shifting from "killing tumors" to "regulating genes." LNP, as one of the most mature non-viral nucleic acid delivery systems currently available, relies on its adjustable lipid composition, good biosafety and pH-responsive charge-conversion capability, and is able to protect siRNA from acid-enzyme degradation, promote cellular uptake, and achieve endosomal escape. Therefore, it overcomes key delivery barriers, such as the poor in vivo stability and low cellular uptake efficiency of naked siRNA. The successful approval of Onpattro fully verified the possibility of clinical translation of the LNP-siRNA delivery platform. However, the current LNP system still has issues, such as insufficient tumor targeting, accumulation in non-target tissues, and difficulty in precisely regulating them in vivo behavior. To overcome the above bottlenecks, researchers have been continuously improving the active tumour-targeting ability and delivery precision of LNPs through methods such as surface functionalization and modification of lipid composition. First, the composition and structure of ionizable LNPs and their targeted delivery mechanism are introduced in this review. then, various targeted modification strategies for tumor siRNA delivery are systematically listed, including peptides, antibodies, amino acids, and receptor-ligand systems, and finally, the current challenges and future directions are summarized.